Document Detail


Insulin for the world's poorest countries.
MedLine Citation:
PMID:  10752719     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the industrialised world, type 1 diabetes rarely results in death from ketoacidosis. The same is not true in many countries in the developing world where insulin availability is intermittent, and insulin may not even be included on national formularies of essential drugs. The life expectancy for a newly diagnosed patient with type 1 diabetes in some parts of Africa may be as short as 1 year. The World Bank has identified 40 highly indebted poor countries (HIPCs) whose national debt substantially exceeds any possibility of repayment without heavy impact on health and social programmes. Incidence and prognosis of type 1 diabetes in HIPCs are lower than in most industrialised countries, and 0.48% of the world's current use of insulin is estimated to be sufficient to treat all type 1 diabetic patients in these countries. A proposal is made for the major insulin manufacturers to donate insulin, at an estimated cost of US$3-5 million per year, as part of a distribution and education initiative for type 1 diabetic patients in the HIPCs. No type 1 diabetic patient in the world's poorest countries need then die because they, or their government, cannot afford insulin.
In industrialized countries, type 1 diabetes rarely results in death from ketoacidosis. The same is not true in many developing countries where insulin availability is intermittent, and insulin may not even be included on national formularies of essential drugs. The life expectancy for a newly diagnosed patient with type 1 diabetes in some parts of Africa may be as short as 1 year. The World Bank has defined 40 highly indebted poor countries (HIPCs) on the basis that debt repayment greatly exceeds the potential incomes, and as a consequence, programs of social investment suffer. Incidence and prognosis of type 1 diabetes in HIPCs are lower than in most industrialized countries, and 0.48% of the world's current use of insulin is estimated to be sufficient to treat all type 1 diabetic patients in these countries. A proposal is made for the major insulin manufacturers to donate insulin, at an estimated cost of US$3-5 million per year, as part of a distribution and education initiative for type 1 diabetic patients in the HIPCs. No type 1 diabetic patients in the world's poorest countries need to die because they, or their government, cannot afford insulin.
Authors:
J S Yudkin
Related Documents :
12048249 - The change in oceanic o(2) inventory associated with recent global warming.
19584379 - Dapagliflozin for the treatment of type 2 diabetes.
21294929 - Comparative effects of glucose and xylose on blood pressure, gastric emptying and incre...
22893399 - The bb rat as a model of human type 1 diabetes.
22873349 - Effect of telmisartan on the expression of adiponectin receptors and nicotinamide adeni...
20628089 - Diabetes risk assessment in mexicans and mexican americans: effects of parental history...
7541259 - Subclinical exocrine pancreatic derangement in human diabetic patients evaluated from p...
18441469 - Effects of metabolic risk factors on production of plasminogen activator inhibitor-1 an...
731029 - Guar gum--its acceptability to diabetic patients when incorporated into baked food prod...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Lancet     Volume:  355     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  2000 Mar 
Date Detail:
Created Date:  2000-04-14     Completed Date:  2000-04-14     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  919-21     Citation Subset:  AIM; IM; J    
Affiliation:
Royal Free and University College London School of Medicine, Whittington Hospital, UK. j.yudkin@ucl.ac.uk
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Africa / epidemiology
Altruism*
Cause of Death
Cross-Sectional Studies
Developing Countries*
Diabetes Mellitus, Type 1 / drug therapy,  mortality*
Humans
Insulin / supply & distribution*
Chemical
Reg. No./Substance:
11061-68-0/Insulin
Comments/Corrections
Comment In:
Lancet. 2000 Jun 17;355(9221):2165-6; author reply 2167   [PMID:  10902654 ]
Lancet. 2000 Jun 17;355(9221):2166; author reply 2167   [PMID:  10902655 ]
Lancet. 2000 Jun 17;355(9221):2165; author reply 2167   [PMID:  10902653 ]
Lancet. 2000 Jun 17;355(9221):2166-7   [PMID:  10902657 ]
Lancet. 2000 Jun 17;355(9221):2166; author reply 2167   [PMID:  10902656 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression.
Next Document:  A biopsy of the use of the Baxter formula to resuscitate burns or do we do it like Charlie did it?